Over 20,000 surgical cases completed using Versius
- The versatile surgical robot Versius has now been used to perform over 20,000 surgical cases across seven specialties with data collected in the clinical registry and digital ecosystem to support sharing insights with surgeons and hospitals
- The small and portable design of Versius has supported over 75% of hospitals to use Versius across two or more specialties
- Reflecting the versatile design of Versius, the system has been most used across urology, general surgery, gynaecology, colorectal surgery, and a growing base of thoracic surgeons
Cambridge, United Kingdom. 21 March 2024 00:01 (GMT). CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery. The innovative small and portable design allows for it to be integrated into busy hospital workflows and easily moved between surgical departments, supporting high utilisation of the system. Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
Versius is suited to assisting surgeons overcome the challenges posed by operating with a minimally invasive approach in surgical specialties that haven’t historically adopted surgical robotics – such as thoracic surgery – with Versius being well suited to operating on the lungs, thymus, and oesophagus. Through small incisions between the patients’ ribs, thoracic surgeons such as the team at Policlinico di Milano in Italy can work precisely and accurately in the chest cavity with Versius, benefitting from its small, fully wristed instruments and 3D HD vision. The uniquely small and modular design of the system allows the system to be set up in a way that gives the surgeon optimal access through the rib cage.
Versius is used across a range of surgical specialties to perform common and complex elective surgical procedures, including prostatectomies, abdominal wall repair, hysterectomies, proctocolectomies, esophagectomies and lobectomies. This includes the use of Versius in combined operations such as endometrial tissue removal, rectopexy and ureteroplasty by the team at Unimed Litoral Hospital in Santa Catarina, Brazil; and fundoplication with Nissen’s technique, gastric bypass and cholecystectomy performed at Hospital Lusíadas Porto, Portugal.
Sangeeta Sawant and Radhika Padmagirison, Consultant Obstetricians and Gynaecologists, East and North Hertfordshire NHS Trust performed the 20,000th procedure using Versius and commented: “It is exciting for us to embark on the robotic journey with CMR. Having done a few cases, we can already feel the difference from the straight stick procedure especially with 3D vision, dexterity of the arms which provide enhanced manipulation which is definitely not possible on straight stick; and we can tell that patients have minimal discomfort at discharge. We are very grateful to have done the 20,000th case and hopefully will be able to do many more.”
Dr Raj Nagarkar, MD and Chief Surgical Oncologist, HCG Manavata Cancer Centre commented: “I have done over 1,000 cases using Versius and the system has been crucial for helping me to deliver excellent oncological care in my centre. Across India, we have a strong demand for the adoption of new innovative technologies, and I am delighted that patients with cancer coming to HCG Manavata can receive treatment using the latest tool to deliver robotic assisted surgery. I have seen patients be able to go home quicker and have reduced blood loss and pain as a result of robotic assisted surgery, and I am pleased to be able to offer this option to our patients.”
Mark Slack, Chief Medical Officer, and Co-founder, CMR Surgical commented: “Surpassing the 20,000 case milestone is a significant achievement that I am tremendously proud of us reaching. When CMR was founded, our mission was to make the benefits of minimal access surgery more accessible to those who need it, with Versius. From a clinical perspective the data we have in the clinical registry, as well as the data generated by Versius is invaluable for supporting product development, clinical research and guiding best practice for surgeons using the system. I look forward to our next clinical milestone as CMR continues to grow, and more patients benefit from robotic-assisted minimal access surgery with Versius.”
Supratim Bose, Chief Executive Officer, CMR Surgical commented: “It is wonderful to be celebrating this historic milestone of Versius being used to complete more than 20,000 surgical procedures around the world. This is a momentous achievement in our journey, and mission to get minimal access surgery to everyone who needs it. Reaching this volume of cases performed by small, medium and large hospitals from around the world is clear evidence that Versius is versatile and suitable for most hospitals and has become well established around the world. Thank you to our customers who have worked alongside us to reach this milestone.”
To support the continued commercial roll out of Versius, further product enhancements are expected to be launched this year, following vLimeLite* – a new imaging technology to visualise ICG, enhancing visualisation during surgery. There are now over 160 Versius installations around the world as CMR continues to make the benefits of robotic-assisted minimal access surgery more accessible to patients globally.
ENDS
Media Contacts:
If you wish to see more, please contact CMR Surgical at:
Press Office, CMR Surgical
T +44(0) 1223 755801
E pressoffice@cmrsurgical.com
Notes to editors:
* vLimeLite is CE marked, please check availability of the product in your country with your local sales representative or your local customer service. The Versius System vLimeLite Instructions for Use, including the approved indications, contraindications and warnings can be found in the product labelling supplied with each Versius System. Not available for sale in the United States.
The Versius Surgical Robotic System
Versius resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure.
Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings.
But it’s more than just a robot. Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.
About CMR Surgical Limited
CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.
Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.
Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.
